DDInter416 DDInter1581
This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s. Clotrimazole falls under the _imidazole_ category of _azole_ antifungals, possessing broad-spectrum antimycotic activity. It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets). As well as its antifungal activity, clotrimazole has become a drug of interest in treating several other diseases such as sickle cell disease, malaria and some cancers. The minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as well as athlete's foot.
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Repaglinide is extensively metabolized in the liver and excreted in bile. Repaglinide metabolites do not possess appreciable hypoglycemic activity. Approximately 90% of a single orally administered dose is eliminated in feces and 8% in urine.
Clotrimazole {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Repaglinide
Clotrimazole {u} (Compound) causes {v} (Side Effect) Oedema
Oedema {u} (Side Effect) is caused by {v} (Compound) Repaglinide
Clotrimazole {u} (Compound) resembles {v} (Compound) Sulfinpyrazone
Sulfinpyrazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Clotrimazole {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Phenelzine
Phenelzine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Clotrimazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is associated with {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Repaglinide
Clotrimazole {u} (Compound) causes {v} (Side Effect) Oedema
Oedema {u} (Side Effect) is caused by {v} (Compound) Oxandrolone
Oxandrolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Clotrimazole {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Repaglinide
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} (Compound) resembles {v} (Compound) Phenylbutazone
Phenylbutazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Clotrimazole {u} (Compound) resembles {v} (Compound) Sulfinpyrazone
Sulfinpyrazone {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Repaglinide
Clotrimazole {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Nifedipine
Nifedipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Clotrimazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Repaglinide (Compound)
Clotrimazole (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Repaglinide (Compound)
Clotrimazole (Compound) resembles Sulfinpyrazone (Compound) and Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Clotrimazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Phenelzine (Compound) and Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Clotrimazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Repaglinide (Compound)
Clotrimazole (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Oxandrolone (Compound) and Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Clotrimazole (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Repaglinide
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone (Compound) resembles Phenylbutazone (Compound) and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Clotrimazole (Compound) resembles Sulfinpyrazone (Compound) and Sulfinpyrazone (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Repaglinide (Compound)
Clotrimazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide